Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Subscribe To Our Newsletter & Stay Updated
